Our group has previously reported that PRMT5 is overexpressed in KRAS-mutant CRC when compared to KRAS wild-type (WT) CRC, and that PRMT5 inhibition exhibited greater therapeutic efficacy in KRAS-mutant CRC when compared to KRAS WT CRC. Here, PRMT5 is linked to colorectal carcinoma.